Ozempic maker’s new weight-loss drug works better, but not quite good enough for analysts - MarketWatch
1. NVO shares dropped 6.6% after CagriSema trial results disappointed. 2. CagriSema achieved a weight loss of 15.7%, below prior expectations. 3. Novo expects regulatory filing for CagriSema by Q1 2026. 4. NVO faces a price war with rival Eli Lilly on weight-loss drugs. 5. NVO stock has fallen 20.2% over the last three months.